323 related articles for article (PubMed ID: 15223016)
1. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
[TBL] [Abstract][Full Text] [Related]
2. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cellular immunotherapy with CD19-specific T cells.
Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
[TBL] [Abstract][Full Text] [Related]
4. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
Michallet AS; Nicolini F; Michallet M
Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
6. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
Cooper LJ; Topp MS; Serrano LM; Gonzalez S; Chang WC; Naranjo A; Wright C; Popplewell L; Raubitschek A; Forman SJ; Jensen MC
Blood; 2003 Feb; 101(4):1637-44. PubMed ID: 12393484
[TBL] [Abstract][Full Text] [Related]
7. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
Ji YH; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(5):495-504. PubMed ID: 12942096
[TBL] [Abstract][Full Text] [Related]
9. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
10. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
[TBL] [Abstract][Full Text] [Related]
12. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
13. Engineering GVL through T cell gene transfer.
Jensen MC
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):5. PubMed ID: 18162214
[No Abstract] [Full Text] [Related]
14. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
[No Abstract] [Full Text] [Related]
15. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Donor leukocyte infusions in myeloid malignancies: new strategies.
Porter DL; Antin JH
Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]